ALNY

NASDAQ · Biotechnology

Alnylam Pharmaceuticals Inc

Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$251.65

+7.33 (+3.00%)

As of Sep 22, 9:35 PM ET ·

Analyst Consensus

Strong Buy

Analysts

Very High

Coverage

Buy 29 76%

Hold 9 24%

Sell 0 0%

Price Target

Analyst Price Target -59.3% upside

Low Target $75.08

Average Target $102.31

High Target $108.98

Current Price $251.65

Current
$251.65

Target
$102.31

$75.08 $102.31 avg $108.98

Scenario Analysis

Bear Case

$75.08

-70.2%

Low target

Base Case

$102.31

-59.3%

Avg target

Bull Case

$108.98

+-56.7%

High target

Risk/Reward

0.8x

Unfavorable

Price in Context

52-Week High

$495.55

-49.2% from high

52-Week Low

$197.81

+27.2% from low

50-Day SMA

$371.56

-32.3% vs SMA

200-Day SMA

$388.35

-35.2% vs SMA

RSI (14)

46.4

Neutral

Target vs 52W High

$102.31

-79.4% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Strong Buy	39	82%	$257.58	-2.9%
AMGN Amgen Inc	Hold	43	47%	$190.87	-53.5%
GILD Gilead Sciences Inc	Strong Buy	37	81%	$362.68	+137.6%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	36	81%	$438.34	-14.9%
REGN Regeneron Pharmaceuticals	Buy	38	68%	$76.80	-90.4%
MRNA Moderna Inc	Hold	30	37%	$149.45	-18.1%
NTRA Natera Inc	Strong Buy	30	87%	$142.91	-63.4%
RVMD Revolution Medicines Inc	Strong Buy	28	93%	$114.11	-40.8%